CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY) - PREBLI

Rafael Esteban Mur0 个研究点目标入组 61 人开始时间: 2012年1月24日最近更新: 2021年12月6日

适应症

试验速览

暂无简介。

•Male and female patients over 18 years of age
•Patients diagnosed with haematological cancer scheduled to receive treatment with rituximab alone or in combination with other chemotherapy
•Evidence of previous exposure to HBV: HBcAb-positive patients
•HBsAg negative patients
•Signed Informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 95
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 3

•Intolerance to any treatment component.
•Co-infection with HIV.
•Presence of hepatocellular carcinoma
•Patients with severe or moderate renal failure
•Liver or kidney transplant or severe renal, lung or neurological diseases that under investigator criteria may interfere in the patient’s participation during the clinical trial.
•Pregnancy or breastfeeding.
•Treatment within the last 30 days with any experimental (non-authorised) drug.
•Any other disease or condition that might render the patient ineligible for the trial.

发起方

Rafael Esteban Mur